4689 related articles for article (PubMed ID: 1673856)
1. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
2. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.
Hersey P; Jamal O; Henderson C; Zardawi I; D'Alessandro G
Int J Cancer; 1988 Mar; 41(3):336-43. PubMed ID: 3346097
[TBL] [Abstract][Full Text] [Related]
3. Expression of the gangliosides GD3 and GD2 on lymphocytes in tissue sections of melanoma.
Hersey P; Jamal O
Pathology; 1989 Jan; 21(1):51-8. PubMed ID: 2668866
[TBL] [Abstract][Full Text] [Related]
4. Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.
Nakakuma H; Horikawa K; Kawaguchi T; Hidaka M; Nagakura S; Hirai S; Kageshita T; Ono T; Kagimoto T; Iwamori M
Jpn J Clin Oncol; 1992 Oct; 22(5):308-12. PubMed ID: 1469793
[TBL] [Abstract][Full Text] [Related]
5. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.
Hoon DS; Irie RF; Cochran AJ
Cell Immunol; 1988 Feb; 111(2):410-9. PubMed ID: 3123073
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of gangliosides in malignant properties of melanomas.
Ohmi Y; Kambe M; Ohkawa Y; Hamamura K; Tajima O; Takeuchi R; Furukawa K; Furukawa K
PLoS One; 2018; 13(11):e0206881. PubMed ID: 30462668
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
8. Ganglioside profiles of experimental melanomas and of their melanosomal fractions.
Vedralová E; Borovanský J; Hach P
Melanoma Res; 1995 Apr; 5(2):87-92. PubMed ID: 7620344
[TBL] [Abstract][Full Text] [Related]
9. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
10. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
11. GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes.
Reilly EB; Antognetti G
Cancer Immunol Immunother; 1992; 35(1):59-62. PubMed ID: 1611624
[TBL] [Abstract][Full Text] [Related]
12. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
Carrel S; Schreyer M; Gross N; Zografos L
Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
[TBL] [Abstract][Full Text] [Related]
13. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3.
Hersey P; Schibeci SD; Townsend P; Burns C; Cheresh DA
Cancer Res; 1986 Dec; 46(12 Pt 1):6083-90. PubMed ID: 3022915
[TBL] [Abstract][Full Text] [Related]
15. Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity.
Kanda S; Cochran AJ; Lee WR; Morton DL; Irie RF
Int J Cancer; 1992 Nov; 52(5):682-7. PubMed ID: 1428227
[TBL] [Abstract][Full Text] [Related]
16. Expression of GD3 disialoganglioside antigen on peripheral T-lymphocytes in patients with disseminated malignant melanoma.
Welte B; Handgretinger R; Rassner G; Fierlbeck G
Exp Dermatol; 1997 Apr; 6(2):64-9. PubMed ID: 9209886
[TBL] [Abstract][Full Text] [Related]
17. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.
Bernhard H; Roth S; Bauerschmitz J; Meyer zum Büschenfelde KH; Dippold W
Int J Cancer; 1992 Jun; 51(4):568-72. PubMed ID: 1376299
[TBL] [Abstract][Full Text] [Related]
18. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
19. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.
Furukawa K; Yamaguchi H; Oettgen HF; Old LJ; Lloyd KO
Cancer Res; 1989 Jan; 49(1):191-6. PubMed ID: 2908845
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
